BASF has set up a pharmaceutical technical laboratory in Navi Mumbai, India citing Asia’s fast growing generic drug manufacturing sector as its target customer base.
Baxter International has agreed to pay Claris Lifesciences $625m (€598m) for three manufacturing facilities and a portfolio of 11 approved injectable drugs.
Helvoet Pharma is to build a €14m ($19m) rubber parenteral packaging component facility in India to meet rising demand for products made to international quality standards.
Pfizer is the latest company to seek greater control of its Indian subsidiary, falling into step with Swiss drug major Novartis which made a similar move late last month.
US-based contract manufacturer AMRI has been busily embracing India
with the purchase and construction of infrastructure to cement
itself in this popular location, delegates heard at this year's
CPhI in Milan.
Sandoz, the generics subsidiary of Swiss pharmaceutical company
Novartis, is rumoured to be planning an acquisition in India in a
move that would give it back the top slot in the sector.
Swiss pharmaceuticals giant Novartis is planning to shut its only
manufacturing facility in India, at Mahad in Maharashtra, because
of increasing competition.